Press releases

7 Jul 2020

UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA[®] (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease

3 Jul 2020

Disposals of own shares

26 Jun 2020

Disposals of own shares

19 Jun 2020

Acquisitions and disposals of own shares

16 Jun 2020

New Capture the Fracture Partnership aims for 25 Percent Reduction in the Incidence of Hip and Vertebral Fractures due to Osteoporosis by 2025

12 Jun 2020

First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara[®] at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis

Press releases

Press releases

Search Press releases

UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA[®] (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease

Disposals of own shares

Disposals of own shares

Acquisitions and disposals of own shares

New Capture the Fracture Partnership aims for 25 Percent Reduction in the Incidence of Hip and Vertebral Fractures due to Osteoporosis by 2025

First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara[®] at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

Global data show real-world effectiveness of romosozumab for patients at high fracture risk

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA[®] (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease

Disposals of own shares

Disposals of own shares

Acquisitions and disposals of own shares

New Capture the Fracture Partnership aims for 25 Percent Reduction in the Incidence of Hip and Vertebral Fractures due to Osteoporosis by 2025

First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara[®] at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis

Choose a Country